Personalized magnetic brain stimulation for parkinsonian disorders
Exploration of the Efficacy of Individualized Transcranial Magnetic Stimulation in the Treatment of Parkinsonian Disorders
This study will try personalized repetitive transcranial magnetic stimulation (rTMS) to see if it eases motor and non-motor symptoms in people with Parkinson's disease, multiple system atrophy, or progressive supranuclear palsy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 30 Years to 80 Years |
| Sex | All |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT07570212 on ClinicalTrials.gov |
What this trial studies
Participants undergo clinical assessments, MRI, and EEG at screening to guide individualized targeting. Treatment consists of 10 daily, individualized rTMS sessions over two weeks with stable medications and rehabilitation routines. Clinical scales, MRI, and EEG are repeated at the end of treatment and again 10 weeks later to measure change. The trial aims to identify which parkinsonian clinical features respond to network-guided rTMS and the magnitude of those effects.
Who should consider this trial
Good fit: Adults aged 30–80 with clinically established or probable Parkinson's disease, multiple system atrophy, or progressive supranuclear palsy at moderate disease stages who can provide informed consent and follow study procedures are ideal candidates.
Not a fit: People with contraindications to TMS (for example intracranial metallic implants), those outside the specified disease stages, or those unable to maintain stable medications or attend daily sessions are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, this approach could reduce motor and non-motor symptoms and improve daily functioning for people with parkinsonian disorders.
How similar studies have performed: Previous rTMS studies in Parkinson's disease have reported modest and mixed symptomatic benefits, while individualized, network-guided rTMS is a newer approach that is not yet proven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Diagnostic Criteria Clinically established or clinically probable Parkinson's Disease (PD) according to the 2015 International Parkinson and Movement Disorder Society (MDS) diagnostic criteria; Clinically established or clinically probable Multiple System Atrophy (MSA) according to the 2022 MDS diagnostic criteria; Clinically probable or clinically possible Progressive Supranuclear Palsy (PSP) according to the 2017 MDS diagnostic criteria. 2. Demographics Aged 30 to 80 years, inclusive; no gender restrictions. 3. Disease Severity and Staging PD: Modified Hoehn and Yahr (H-Y) stage 2-4; MSA: Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV stage 1-4; PSP: Modified Rankin Scale (mRS) grade 2-4. 4. Informed Consent and Compliance Ability to understand and comply with the study requirements and provide written informed consent. Exclusion Criteria: 1. Contraindications to TMS Presence of intracranial metallic implants or other foreign bodies, including but not limited to cochlear implants, cardiac pacemakers, or internal metallic/magnetic fragments. 2. Contraindications to EEG and MRI EEG: Known allergy to conductive paste or other EEG-related contraindications. MRI: History of claustrophobia, presence of MRI-incompatible implants, or extensive tattoos. 3. Concurrent Physical Therapies Currently receiving Transcranial Magnetic Stimulation (TMS) or other therapeutic physical modalities, such as Transcranial Direct Current Stimulation (tDCS). 4. Unstable Medical Conditions Presence of unstable systemic diseases requiring urgent pharmacological or surgical intervention. 5. Neurological and Psychiatric History Personal or family history of epilepsy; History of moderate-to-severe psychiatric or psychological disorders; Chronic insomnia or regular use of sedative-hypnotics; Current use of medications that significantly alter central nervous system excitability.
Where this trial is running
Beijing, Beijing Municipality
- Peking University First Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Zhaoxia Wang, M.D. — Peking University First Hospital
- Study coordinator: Luhua Wei, M.D.
- Email: weiluhua2008@outlook.com
- Phone: +8615120079081
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.